Access Bio 2025 Annual Report: Revenue Plunges 73% but Treasury Stock Cancellation of 6.8% Boosts Shareholder Value
Access Bio's 2025 consolidated revenue plummeted 73% year-over-year to $21.98 million due to declining COVID-19 diagnostic demand, swinging to an operating loss of $44.55 million and controlling interest net loss of $57.74 million.
Total assets decreased 16% from impairment charges of $32.35 million and lower lease liabilities, while the debt ratio fell to 8.9%. The company maintains ample cash of $225.34 million and net financial assets of $288.42 million, indicating solid financial health.
In September 2025, the board resolved to cancel all 2,553,998 treasury shares representing 6.8% of outstanding shares, which is expected to boost earnings per share. The cancellation is subject to shareholder approval at the March 2026 AGM and is scheduled for late April 2026.
Post-period, the company decided to acquire equity in AAC Holdings for KRW 15 billion and RF Bio for KRW 57 billion in January 2026, pursuing business diversification, though this adds short-term financial burden and uncertainty.
Major ongoing litigations include a fee dispute with Gredale LLC and a lease dispute with PP Tango NJ 1 LLC, with outcomes unpredictable.
No convertible bonds or additional equity were issued during the period; all previous convertibles were fully converted, leaving no outstanding convertible bonds.
[AI Summary]Access Bio faced a sharp revenue decline and impairment-driven losses in 2025 due to the COVID-19 endemic shift. However, its strong cash position and planned treasury stock cancellation signal shareholder commitment. While new investments and lawsuits introduce near-term volatility, financial stability and capital efficiency efforts support long-term shareholder value.
KOSDAQ Filing Information
[Correction of Description] Business Report (2025.12)